
Lakefront Biotherapeutics gains value with new model and Gilead partnership after Ouro acquisition
Lakefront Biotherapeutics, formerly Galapagos, rebranded and acquired Ouro Medicines' assets with Gilead, creating a new drug development platform. The company has €2.24 billion in liquidity to support clinical trials for gamgertamig, a drug targetin...





